Day One Biopharmaceuticals, Inc. logo DAWN - Day One Biopharmaceuticals, Inc.

Inactive Ticker DAWN is not actively trading. Quotes and analytics may be stale.
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 6
HOLD 6
SELL 0
STRONG
SELL
0
| PRICE TARGET: $21.50 DETAILS
HIGH: $21.50
LOW: $21.50
MEDIAN: $21.50
CONSENSUS: $21.50
DOWNSIDE: 0.14%
Metric 2025 2024 2023 2022 2021 2020 2019
Revenue
Revenue 158.2 131.2 0 0 0 0 0
Cost of Revenue 17.2 5.3 0 0 0 0 0
Gross Profit 141.0 125.9 0 0 0 0 0
Operating Expenses
R&D Expenses 148.1 227.7 130.5 85.6 43.6 9.1 13.9
SG&A Expenses 120.6 115.5 75.5 61.3 29.2 4.7 1.0
Other Expenses 0 0 0 0 0 (0.0) 0
Operating Expenses 268.7 343.2 206.1 146.9 72.7 13.8 14.9
Operating Income
Operating Income (127.8) (217.3) (206.1) (146.9) (72.7) (13.8) (14.9)
Interest Expense 0 0 0 0 0 0.0 2.1
Interest Income 18.5 19.7 17.2 4.7 0.0 0 0
Profitability
EBITDA (124.0) (215.2) (205.7) (146.4) (72.5) 16.4 (0.0)
EBIT (127.8) (217.3) (206.1) (146.9) (72.7) 0 (14.9)
Income Before Tax (109.3) (88.4) (188.9) (142.2) (72.8) (43.8) (17.0)
Income Tax Expense (2.0) 7.1 0 0 0 0 0
Net Income (107.3) (95.5) (188.9) (142.2) (70.6) (40.5) (12.6)
Per Share Data
EPS (Basic) -1.04 -1.02 -2.37 -2.02 -1.14 -0.65 -0.24
EPS (Diluted) -1.04 -1.02 -2.37 -2.02 -1.14 -0.65 -0.24
Shares Outstanding 103.4 93.6 79.8 65.5 62.0 61.9 61.9
Metric 2025 2024 2023 2022 2021 2020 2019
Current Assets
Cash & Cash Equivalents 197.1 125.0 230.8 85.3 284.3 43.7 27.3
Short-Term Investments 244.0 406.8 135.6 257.0 0 0 0
Net Receivables 26.7 13.9 0 0 0 0 0
Inventory 6.3 3.3 0 0 0 0 0
Other Current Assets 10.9 4.4 2.4 1.0 1.0 1.3 0
Total Current Assets 485.1 562.3 375.3 347.9 289.4 45.1 27.3
Non-Current Assets
Property, Plant & Equipment 4.5 4.7 0.6 0.7 0.3 0.5 0
Goodwill 0 0 0 0 0 0 0
Intangible Assets 18.0 15.6 0 0 0 0 0
Long-Term Investments 0 0 0 0 0 0 0
Other Non-Current Assets 0.2 0.1 0.2 0.5 0.2 0.1 0
Total Non-Current Assets 22.7 20.5 0.8 1.2 0.5 0.6 0
Total Assets 507.8 582.8 376.0 349.1 289.8 45.7 27.3
Current Liabilities
Account Payables 3.7 3.3 2.6 0.3 1.7 0.2 0.1
Short-Term Debt 0.2 0.0 0.4 0.4 0.2 0 0
Deferred Revenue 2 1.6 0 0 0 0 0
Other Current Liabilities 54.6 54.7 17.4 9.8 0.1 0.0 1.5
Total Current Liabilities 60.5 73.5 29.5 16.6 8.7 2.0 2.0
Non-Current Liabilities
Long-Term Debt 2.6 0 0 0 0 0 0
Deferred Tax Liabilities 0 0 0 0 0 0 0
Other Non-Current Liabilities 3.5 0.8 0 0 0 0 30.5
Total Non-Current Liabilities 6.1 6.6 0 0.4 0.0 0.2 30.5
Total Liabilities 66.7 80.0 29.5 17.0 8.7 2.2 32.5
Stockholders' Equity
Common Stock 0.0 0.0 0.0 0.0 0.0 2.6 2
Retained Earnings (661.4) (554.1) (458.6) (269.7) (127.5) (56.8) (12.8)
Accumulated Other Comprehensive Income 0.1 0.1 0.0 (0.1) 0 0 0.0
Total Stockholders' Equity 441.2 502.8 346.5 332.0 281.1 37.8 (10.7)
Total Liabilities & Equity 507.8 582.8 376.0 349.1 289.8 45.7 27.3
Debt Metrics
Total Debt 2.8 2.6 0.4 0.8 0.2 0.4 0
Net Debt (194.3) (122.4) (230.4) (84.4) (284.1) (43.3) (27.3)
Metric 2025 2024 2023 2022 2021 2020 2019
Operating Activities
Net Income (107.3) (95.5) (188.9) (142.2) (72.8) (43.8) (17.0)
Depreciation & Amortization 3.5 2.0 0.4 0.5 0.2 0.2 0
Stock-Based Compensation 44.4 48.3 39.3 27.2 13.3 0.5 0.1
Change in Working Capital (28.9) 26.5 9.4 6.6 2.7 (0.4) 0.4
Other Non-Cash Items (15.4) (59.4) (7.1) (2.0) 8 30.0 11.9
Operating Cash Flow (103.8) (78.1) (146.9) (109.9) (48.5) (13.5) (4.5)
Investing Activities
Capital Expenditure (0.3) (2.2) (3.2) (0.0) (8) (0.1) 0
Acquisitions 0 0 0 0.3 0 0 0
Purchases of Investments (695.8) (658.6) (443.8) (394.2) 0 0 0
Sales/Maturities of Investments 874.2 393.9 575.4 139.2 0 0 0
Other Investing Activities (3.5) 35.9 (3) (0.3) 0 0 0
Investing Cash Flow 174.6 (231.0) 128.4 (255.1) (8) (0.1) 0
Financing Activities
Net Debt Issuance 0 0 0 0 0 0 1
Stock Repurchased 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0
Other Financing Activities 0 25.1 0 4.3 0.3 0 0
Financing Cash Flow 1.2 203.3 164.0 165.9 297.1 30.0 30.9
Cash Position
Net Change in Cash 72.1 (105.8) 145.5 (199.0) 240.6 16.4 26.4
Cash at Beginning 125.0 230.8 85.3 284.3 43.7 27.3 0.9
Cash at End 197.1 125.0 230.8 85.3 284.3 43.7 27.3
Free Cash Flow (104.1) (80.3) (150.1) (109.9) (56.5) (13.6) (4.5)
Key Metrics 2025 2024 2023 2022 2021 2020 2019
Income Statement
Revenue 158.2 131.2 0 0 0 0 0
Gross Profit 141.0 125.9 0 0 0 0 0
Operating Income (127.8) (217.3) (206.1) (146.9) (72.7) (13.8) (14.9)
Net Income (107.3) (95.5) (188.9) (142.2) (70.6) (40.5) (12.6)
EPS (Diluted) -1.04 -1.02 -2.37 -2.02 -1.14 -0.65 -0.24
Balance Sheet
Cash & Equivalents 197.1 125.0 230.8 85.3 284.3 43.7 27.3
Total Assets 507.8 582.8 376.0 349.1 289.8 45.7 27.3
Total Debt 2.8 2.6 0.4 0.8 0.2 0.4 0
Stockholders' Equity 441.2 502.8 346.5 332.0 281.1 37.8 (10.7)
Cash Flow
Operating Cash Flow (103.8) (78.1) (146.9) (109.9) (48.5) (13.5) (4.5)
Capital Expenditure (0.3) (2.2) (3.2) (0.0) (8) (0.1) 0
Free Cash Flow (104.1) (80.3) (150.1) (109.9) (56.5) (13.6) (4.5)